mevonlerbart

**Mevonlerbart** is one of two fully human IgG4 monoclonal antibodies in REGN1908-1909, a 1:1 clinical mixture targeting **Fel d 1**, the major cat allergen. Developed by **Regeneron Pharmaceuticals** using VelocImmune® transgenic mouse technology, it neutralizes Fel d 1 to prevent allergic reactions by binding distinct epitopes, reducing symptoms in cat allergy. Primary indications include **cat allergy** and associated conditions like allergic asthma and conjunctivitis; it reached **Phase 3** trials but faced discontinuation of one study due to futility in 2022, while remaining active in others.[1]

Other names

Mevonlerbartanti-cat allergen Fel d 1 monoclonal antibody regn-1909immunoglobulin G4-kappa, anti-[Fel d 1 (Felis silvestris catus (domestic cat) allergen 1)], Homo sapiens monoclonal antibody